Known other respiratory disorders or signs for other respiratory disorders (e.g. asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis). 
Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus). 
Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ) 
Having undergone lung surgery (e.g. lung resection including lung volume reduction surgery, lung transplant) or subjects scheduled for surgery. 
Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor). 
Subjects receiving chronic or prophylactic antibiotic therapy. 
Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety. 
Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse. 
History of depression. 
History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol. 
Moderate or severe COPD exacerbation (requiring corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization) within the 4 weeks prior to Visit 1 
Lower respiratory tract infection within the 4 weeks prior to Visit 1 . 
Pregnant or lactating female and female of childbearing potential. 
Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK). 
Subject participated in an investigational drug study within 30 days prior to Visit 1       
    

NCT00527826_exc_T1
Condition
respiratory disorders
NCT00527826_exc_T2
Condition
signs for respiratory disorders
NCT00527826_exc_T3
Condition
asthma
NCT00527826_exc_T4
Condition
lung cancer
NCT00527826_exc_T5
Condition
sarcoidosis
NCT00527826_exc_T6
Condition
tuberculosis
NCT00527826_exc_T7
Condition
lung fibrosis
NCT00527826_exc_T8
Condition
cystic fibrosis
NCT00527826_exc_T9
Condition
bronchoectasis
NCT00527826_exc_T10
Scope
asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis
NCT00527826_exc_T11
Scope
respiratory disorders or signs for other respiratory disorders
NCT00527826_exc_T12
Condition
inflammatory disease
NCT00527826_exc_T13
Condition
COPD
NCT00527826_exc_T14
Condition
rheumatoid arthritis
NCT00527826_exc_T15
Condition
systemic lupus erythematosus
NCT00527826_exc_T16
Negation
other than
NCT00527826_exc_T17
Condition
alpha-1-antitrypsin deficient
NCT00527826_exc_T18
Procedure
lung surgery
NCT00527826_exc_T19
Procedure
lung resection
NCT00527826_exc_T20
Procedure
lung volume reduction surgery
NCT00527826_exc_T21
Procedure
lung transplant
NCT00527826_exc_T22
Procedure
surgery
NCT00527826_exc_T23
Observation
scheduled
NCT00527826_exc_T24
Drug
medication from Visit 1
NCT00527826_exc_T25
Drug
monoamine oxidase inhibitors
NCT00527826_exc_T26
Drug
tricyclic antidepressants
NCT00527826_exc_T27
Drug
ritonavir
NCT00527826_exc_T28
Drug
cytochrome P450 3A4 inhibitor
NCT00527826_exc_T29
Scope
monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor)
NCT00527826_exc_T30
Procedure
prophylactic antibiotic therapy
NCT00527826_exc_T31
Procedure
chronic antibiotic therapy
NCT00527826_exc_T32
Condition
uncontrolled disease
NCT00527826_exc_T33
Condition
psychological disorders
NCT00527826_exc_T34
Condition
alcohol abuse
NCT00527826_exc_T35
Condition
drug abuse
NCT00527826_exc_T36
Condition
solvent abuse
NCT00527826_exc_T37
Condition
drug sensitivity
NCT00527826_exc_T38
Condition
allergic reaction
NCT00527826_exc_T39
Drug
corticosteroids
NCT00527826_exc_T40
Drug
salmeterol
NCT00527826_exc_T41
Scope
corticosteroids or salmeterol
NCT00527826_exc_T42
Scope
drug sensitivity or clinically significant allergic reaction
NCT00527826_exc_T43
Condition
COPD exacerbation
NCT00527826_exc_T44
Qualifier
severe
NCT00527826_exc_T45
Qualifier
Moderate
NCT00527826_exc_T46
Scope
Moderate or severe
NCT00527826_exc_T47
Drug
corticosteroids
NCT00527826_exc_T48
Drug
corticosteroids
NCT00527826_exc_T49
Qualifier
increased dosage
NCT00527826_exc_T50
Drug
antibiotics
NCT00527826_exc_T51
Visit
hospitalization
NCT00527826_exc_T52
Scope
corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization
NCT00527826_exc_T53
Temporal
within the 4 weeks prior to Visit 1
NCT00527826_exc_T54
Condition
Lower respiratory tract infection
NCT00527826_exc_T55
Temporal
within the 4 weeks prior to Visit 1
NCT00527826_exc_T56
Condition
Pregnant
NCT00527826_exc_T57
Condition
lactating
NCT00527826_exc_T58
Person
female
NCT00527826_exc_T59
Condition
childbearing potential
NCT00527826_exc_T60
Person
female
NCT00527826_exc_T61
Scope
rheumatoid arthritis and systemic lupus erythematosus
NCT00527826_exc_T62
Scope
inflammatory disease, other than COPD
NCT00527826_exc_T63
Scope
lung volume reduction surgery, lung transplant
NCT00527826_exc_T64
Reference_point
Visit 1
NCT00527826_exc_T65
Reference_point
Visit 1
NCT00527826_exc_T67
Observation
participated in an investigational drug study
NCT00527826_exc_T68
Temporal
within 30 days prior to Visit 1
NCT00527826_exc_T69
Reference_point
Visit 1
NCT00527826_exc_T70
Qualifier
significant
NCT00527826_exc_T71
Qualifier
severely
NCT00527826_exc_T72
Observation
History of
NCT00527826_exc_T73
Condition
depression
NCT00527826_exc_T75
Scope
alcohol, drug or solvent abuse